• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Potential Risk of Other-Cause Mortality Due to Long-Term Androgen Deprivation Therapy in Elderly Patients with Clinically Localized Prostate Cancer Treated with Radiotherapy—A Confirmation Study
【24h】

Potential Risk of Other-Cause Mortality Due to Long-Term Androgen Deprivation Therapy in Elderly Patients with Clinically Localized Prostate Cancer Treated with Radiotherapy—A Confirmation Study

机译：由于长期抗衰性治疗的其他因素死亡率的潜在风险，患有放射治疗的临床局部前列腺癌的临床局部前列腺癌 - A确认研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Androgen deprivation therapy (ADT) is used to improve overall survival (OS) in prostate cancer treatment; however, we encountered that long-term ADT in elderly patients may be related to high other-cause mortality (OCM). This study aimed to confirm the potential risk associated with long-term ADT in elderly patients using a different large cohort. A comparison analysis was conducted between the ≥2- and 2-year ADT groups using open, large data from 1840 patients with clinically localized prostate cancer treated with radiotherapy (1172 treated with high-dose-rate brachytherapy (HDR) + external beam radiotherapy (EBRT) and 668 treated with external beam radiotherapy). The OCM-free survival (OCMFS), overall survival, and prostate cancer-specific survival rates were measured. The 10-year OCMFS rates in patients aged ≥75 years were 94.6% and 86% in the 2- and ≥2-year ADT groups, respectively, but were 96.3% and 93.5% ( p = 0.0006) in their younger counterparts. If dividing into HDR and EBRT groups. This inclination was found in brachytherapy group but not in EBRT group. The overall survival rate was also lower in the elderly patients in the ≥2-year ADT group than in the 2-year ADT group; however, the 10-year prostate cancer-specific survival rate was the same in both groups. Long-term ADT in elderly patients resulted in not only higher OCM rates but also poorer OS rates; therefore, longer-term ADT in elderly patients should be performed with meticulous care.
机译：雄激素剥夺治疗（ADT）用于改善前列腺癌治疗中的整体存活（OS）;然而，我们遇到的是，老年患者的长期ADT可能与高其他导致死亡率（OCM）有关。本研究旨在确认使用不同大型队列的老年患者长期ADT相关的潜在风险。使用Open的≥2-和<2年ADT组进行比较分析，从1840名临床局部化前列腺癌治疗放疗（1172用高剂量速率近距离放射治疗（HDR）+外梁放射治疗（EBRT）和668用外梁放射治疗）。测量无OCM的存活（OCMFS），整体存活和前列腺癌特异性存活率。 ≥75岁的患者的10年ocmfs率分别为94.6％，分别为94.6％和86％，较年轻的对应物中的96.3％和93.5％（p = 0.0006）。如果分为HDR和EBRT组。这种倾向在近距离放射治疗组中发现，但不在EBRT组中发现。 ≥2年ADT组的老年患者的整体存活率也比<2年ADT组;然而，两组的10年前列腺癌细胞的存活率相同。老年患者的长期ADT导致OCM率不仅更高，而且较差的操作系统率;因此，长期ADT在老年患者中应进行细致的护理进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号